Hye-Young Sung; Jeong-Wook Park; Joong-Seok Kim

doi:10.14802/jmd.14002

Articles

Page Path: HOME > J Mov Disord > Volume 7(1); 2014 > Article

Original Article The Frequency and Severity of Gastrointestinal Symptoms in Patients with Early Parkinson’s Disease: Hye-Young Sung^a, Jeong-Wook Park^b, Joong-Seok Kim^b; Journal of Movement Disorders 2014;7(1):7-12.
DOI: https://doi.org/10.14802/jmd.14002
Published online: April 30, 2014

^aDivision of Gastroenterology, Digestive Disease Research Institute, Department of Internal Medicine, Wonkwang University Sanbon Hospital, Gunpo, Korea

^bDepartment of Neurology, College of Medicine, The Catholic University of Korea, Seoul, Korea

Corresponding author: Joong-Seok Kim, MD, PhD, Department of Neurology, College of Medicine, The Catholic University of Korea, Seoul St. Mary’s Hospital, 222 Banpo-daero, Seocho-gu, Seoul 137-701, Korea / Tel: +82-2-2258-6078 / Fax: +82-2-599-9686 / E-mail: neuronet@catholic.ac.kr

• Received: February 15, 2014 • Revised: February 20, 2014 • Accepted: February 20, 2014

18,436 Views
185 Download
58 Web of Science
61 Crossref

Full Article

Download PDF

ABSTRACT

Objective
Although gastrointestinal dysfunctions occur in the majority of patients with Parkinson’s disease (PD), they are often unrecognized because many patients remain relatively asymptomatic in the early stage. We investigated the frequency of gastrointestinal symptoms in patients with PD using newly developed gastrointestinal symptom questionnaires.
Methods
Early PD patients with a symptom duration not exceeding 3 years were included in this study. All PD patients were evaluated using a questionnaire, which consisted of three relevant domains: oropharyngoesophageal (10 items); gastric (3 items); and intestinal-anorectal (7 items). The frequency of symptoms was calculated as a proportion with an item score ≥ 2.
Results
Of the 54 patients enrolled, 48 patients (88.9%) responded that bowel symptoms developed before the onset of Parkinsonian motor symptoms, and four patients reported that the onset of two types of symptoms (i.e., bowel and neurological) occurred approximately simultaneously, with only months between them. The frequencies of gastrointestinal symptoms are as follows: speech disturbance (40.7%), drooling (24.1%), sense of getting stuck (31.5%), choking (27.8%), globus pharyngis (16.7%), repetitive deglutition (29.6%), pain during swallowing (5.6%), food regurgitation (3.7%), acid reflux (7.4%), nausea/vomiting (11.1%), early satiety (16.7%), postprandial fullness (14.8%), epigastric soreness (9.3%), abdominal pain (3.7%), constipation (46.3%), excessive strain during defecation (33.3%), fecal incontinence (7.4%), tenesmus (20.4%), loose stool or diarrhea (3.7%), and difficulty in relaxing anal sphincter (11.1%). Two patients were scored at zero.
Conclusions
Our findings confirm that gastrointestinal dysfunction occurs in early PD in relatively high frequency.
Keywords: Parkinson’s disease; Gastrointestinal symptoms; Frequency; Severity

Gastrointestinal (GI) symptoms are relatively common in patients suffering from Parkinson’s disease (PD), and these symptoms can be a significant burden on patients and their caregivers. Recent advances in neuropathology address the role of autonomic nuclei in the brainstem and the enteric nervous system in the control of gastrointestinal function, explaining early involvement of this function in PD.1,2

The under-recognition and low levels of awareness of the presence of gastrointestinal dysfunctions by patients, caregiver, and health professionals result in underreporting and a low frequency of complaints. Early detection and effective intervention can help prevent the serious consequences in the quality of life. Several questionnaires have previously been developed for screening GI symptoms;3–6 however, many of these questionnaires relied on specific, subjective complaints and did not include many types of symptoms.

We developed new gastrointestinal symptom questionnaires and evaluated the prevalence of gastrointestinal symptoms in early PD patients.

Patients: Consecutive early PD patients were enrolled from the Movement Disorders Clinic at Seoul St. Mary’s Hospital, Seoul, Korea. A clinical diagnosis of PD was made according to the UK brain bank criteria.7 None of the patients had ever taken medication for PD. The evaluation procedure included a detailed medical and drug history, a physical and neurological examination and a brief neuropsychological assessment. Excluded from the study were patients with the following: 1) neurological abnormalities related to atypical PD or secondary Parkinsonism, 2) patients with diabetic neuropathy, and 3) patients taking medications known to influence gastrointestinal motility, such as levodopa, dopamine agonists, anticholinergics, or GI dysmotility remedies.; This study was approved by the local ethics committee, and all subjects gave their consent to participate.
Clinical assessments: All patients were subsequently evaluated using the Unified Parkinson’s Disease Rating Scale (UPDRS), the Hoehn and Yahr (H&Y) stage, and the Korean version of the Schwab and England activities of daily living. The patients were also asked to complete a self-administered scale to evaluate the presence and frequency or severity of bowel symptoms during the last 3 months. The self-administered questionnaire consisted of the following 20 items (Table 1): 1) speech disturbance, 2) drooling, 3) sense of getting stuck, 4) choking, 5) globus pharyngis, 6) repetitive deglutition, 7) pain during swallowing, 8) food regurgitation, 9) acid reflux, 10) nausea/vomiting, 11) early satiety, 12) postprandial fullness, 13) epigastric soreness, 14) abdominal pain, 15) constipation, 16) excessive strain during defecation, 17) fecal incontinence, 18) tenesmus, 19) loose stool or diarrhea, and 20) difficulty in relaxing anal sphincter. Each symptom was scored with respect to either the frequency [1 = rare (< 1/week), 2 = often (1/week), 3 = frequent (several times per week), and 4 = always (daily or all the time)] or severity (0 = no or minimum, 1 = mild symptoms present but causing little distress or disturbance, 2 = moderate symptoms causing some distress or disturbance, and 3 = severe symptoms representing a major source of distress or disturbance) of the symptom. The overall score was calculated by multiple severity and frequency scores.
Data analysis: Patients were categorized into the following two subgroups: 1) patients with no or mild problems (a score for each item of ≤ 1) and 2) patients with moderate-to-severe problems (a score for each item of ≥ 2), and the frequencies of each symptom were calculated using this categorical variable. Items were also grouped into three relevant domains: oropharyngoesophageal (10 items), gastric (3 items), and intestinal-anorectal (7 items). The symptom scores were also compared with Parkinsonian motor symptoms. Statistical analyses were performed using the Statistical Package for the Social Sciences (SPSS) version 15.0 (SPSS Inc., Chicago, IL, USA), and the statistical significance level was established at p < 0.05.

RESULTS

Among the 54 patients enrolled, 22 were men and 32 were women. The mean age at examination was 67.1 ± 10.3 years (range, 33–86 years) and the mean motor symptom duration was 14.7 ± 9.3 months (range, 1–36 months). The severity of Parkinsonian motor symptoms was as follows: mean total UPDRS score was 25.1 ± 18.6 (part 1, 2.3 ± 2.3; part 2, 8.3 ± 6.9; part 3, 14.4 ± 10.6), and the mean H&Y stage was 1.6 ± 0.4. Fourteen patients were scored as H&Y stage 1, 20 patients as stage 1.5, and 20 patients as stage 2.

The frequencies of gastrointestinal symptoms are as follows (Table 1, Figure 1): speech disturbance (40.7%), drooling (24.1%), sense of getting stuck (31.5%), choking (27.8%), globus (16.7%), fragmented deglutition (29.6%), pain during swallowing (5.6%), food regurgitation (3.7%), acid reflux (7.4%), nausea/vomiting (11.1%), early satiety (16.7%), postprandial fullness (14.8%), epigastric soreness (9.3%), abdominal pain (3.7%), constipation (46.3%), excessive strain during defecation (33.3%), fecal incontinence (7.4%), tenesmus (20.4%), loose stool or diarrhea (3.7%), and difficulty in relaxing anal sphincter (11.1%). Only two patients scored 0 on the self-administered scale. Forty-eight patients (88.9%) responded that the bowel symptoms developed before the onset of Parkinsonian motor symptoms and worsened after the onset, and four patients reported that the onset of two types of symptoms (i.e., bowel and neurological) occurred approximately simultaneously, with only months between them.

The gastrointestinal symptoms were positively correlated with the UPDRS scores and, in particular, the activity of daily living (ADL) portion of the scores (Figure 2). However, neither the specific motor subtype nor the disease duration was associated with the severity of bowel symptoms.

DISCUSSION

The results of this study suggest that bowel symptoms are present in a majority of early, non-treated PD patients, even before the onset of clinical motor symptoms. The most frequent symptoms found in our patients were difficulty with deglutition and constipation. Dysphagia in patients with PD may be associated with abnormalities found during the oral to esophageal stages of swallowing.8 Dysphagia can result from the motor symptoms of PD involving the oropharyngeal muscles or can occur from defective coordination of the oropharyngeal and esophageal musculature resulting from brainstem involvement.9 About half of the patients with early PD in our study reported a variety of complaints associated with dysphagia. In particular, repetitive deglutition was predominantly related to oropharyngoesophageal dysfunction. Recently, we clearly showed that a majority of early PD patients underwent repetitive swallow attempts (double or triple swallow pattern) for a single bolus.8 These abnormal swallow patterns were shown to be directly associated with abnormal peristalsis in the esophageal manometry. Repetitive deglutition might be a reactive response necessary to clear remnant bolus material on the pharynx. Such a repetitive deglutition was closely related to esophageal dysfunction though the vagal inhibitory dysfunction. Under normal physiological conditions, while there are repetitive swallow attempts, esophageal peristalsis only responds to the last stimuli, called deglutitive inhibition. Normal deglutitive inhibition indicates intact vagal inhibitory function. Deglutition-evoked peristaltic sequences are mediated via vagal efferent nerves, and peristalsis occurs with active inhibition followed by sequential esophageal contractions that are centrally mediated.10 Therefore, repetitive deglutition may be the most relevant dysfunction, due to its association with esophageal dysmotility, and the above described abnormal deglutitive inhibition provides further evidence of neuronal degeneration of the brain stem swallowing center or abnormalities of the peripheral vagus nerve in patients with early PD.8

Early-stage PD patients in our study showed dysfunctions of the proximal part of the gastrointestinal system, encompassing the stomach and small intestine. Prior reports have suggested that impaired gastric motility is associated with different medications used for the treatment of PD, especially in those patients with response fluctuation. Although major pathological changes in the enteric nervous system were described, some previous studies indicate that the presence of gastroparesis in only 7.5% of PD patients was related to PD itself.11,12 In this study, we show that the proportions of gastric symptoms ranged from 3.7% to 16.7%. Gastric symptoms are a well-recognized manifestation of PD, which can cause not only nausea and other symptoms, such as gastroparesis, but can also affect drug absorption.13 In addition, antiparkinson medications may further exacerbate these symptoms. Therefore, it is important that clinicians help patients with PD find and overcome these disabling symptoms.

The most common gastrointestinal symptoms in our study were related to constipation and difficulty in defecation. Constipation and defecatory dysfunction in patients with PD may be associated with abnormalities occurring during colonic inertia to the anal outlet.14 Defecatory dysfunction is a consequence of uncoordinated action of the muscles involved with defecation. Relaxation of the puborectalis muscle allows for the opening of the anorectal angle and perineal descent, facilitating fecal expulsion. This functional outlet obstruction may cause both excessive straining and a sense of incomplete emptying, or sometimes, may induce painful defecation. 15–17 Another mechanism appears to involve the colonic musculature, which induces a slow passage of feces through the colon.14 Several studies have demonstrated considerably prolonged mean colonic transit time in PD patients.18

Gastrointestinal symptoms were correlated with the UPDRS score, particularly the ADL score. This suggests that the severity of motor symptoms might be closely related to enteric involvement, which is distinct from the degree of nigrostriatal involvement, and other neurotransmitter systems can be selectively affected.

In summary, most of the included patients with early PD had several instances of gastrointestinal symptoms. Many patients reported that these symptoms developed before the clinical motor manifestation of PD. These findings suggest selective involvement of either the brain stem and/or the enteric nervous system at an early stage of PD. The more severe and frequent gastrointestinal symptoms were associated with severe motor symptoms but did not correlate with the duration of PD. Comprehensive screening of gastrointestinal symptoms in patients with early-stage PD can facilitate prompt recognition and effective therapeutic interventions for significant bowel dysfunctions.

Notes

Conflicts of Interest

The authors have no financial conflicts of interest.

Figure 1

Gastrointestinal symptom frequencies in early Parkinson’s disease patients.

Figure 2

Correlation between gastrointestinal symptom score and Unified Parkinson’s Disease Rating Scale (UPDRS); (A) total and (B) activity of daily living (ADL; part 2).

Table 1

Score distribution of the gastrointestinal symptom scale

Measure	Mean	SD	Max.
Speech disturbance	2.17	3.08	15
Drooling	1.54	2.51	10
Sense of getting stuck	1.91	2.02	6
Choking	1.76	2.05	8
Globus (foreign body sensation)	1.02	2.10	10
Repetitive deglutition	1.89	2.60	10
Pain during swallowing	0.72	1.25	5
Food regurgitation	0.50	2.14	15
Acid reflux	0.74	2.42	15
Nausea/vomiting	0.94	2.09	15
Oropharyngoesophageal subdomain	13.18	11.17	48
Early satiety	1.48	3.16	15
Postprandial fullness	0.91	1.50	5
Epigastric soreness	0.87	1.74	8
Gastric subdomain	3.26	4.74	23
Abdominal pain	0.93	1.93	12
Constipation	2.83	2.70	10
Excessive strain during defecation	2.35	2.69	10
Fecal incontinence	0.41	1.12	6
Tenesmus	1.65	2.45	15
Loose stool or diarrhea	0.22	0.92	6
Difficulty in relaxing anal sphincter	0.59	1.28	5
Intestinal-anorectal subdomain	8.98	8.00	33
Total gastrointestinal symptom score	25.43	18.62	97

SD: standard deviation, Min.: minimum, Max.: maximum.

REFERENCES

1. Braak H, de Vos RA, Bohl J, Del Tredici K. Gastric alpha-synuclein immunoreactive inclusions in Meissner’s and Auerbach’s plexuses in cases staged for Parkinson’s disease-related brain pathology. Neurosci Lett 2006;396:67–72.Article PubMed
2. Hawkes CH, Del Tredici K, Braak H. Parkinson’s disease: a dual-hit hypothesis. Neuropathol Appl Neurobiol 2007;33:599–614.Article PubMed PMC
3. Edwards LL, Pfeiffer RF, Quigley EM, Hofman R, Balluff M. Gastrointestinal symptoms in Parkinson’s disease. Mov Disord 1991;6:151–156.Article PubMed
4. Byrne KG, Pfeiffer R, Quigley EM. Gastrointestinal dysfunction in Parkinson’s disease. A report of clinical experience at a single center. J Clin Gastroenterol 1994;19:11–16.Article PubMed
5. Edwards LL, Quigley EM, Pfeiffer RF. Gastrointestinal dysfunction in Parkinson’s disease: frequency and pathophysiology. Neurology 1992;42:726–732.Article PubMed
6. Cersosimo MG, Raina GB, Pecci C, Pellene A, Calandra CR, Gutiérrez C, et al. Gastrointestinal manifestations in Parkinson’s disease: prevalence and occurrence before motor symptoms. J Neurol 2013;260:1332–1338.Article PubMed
7. Gibb WR, Lees AJ. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson’s disease. J Neurol Neurosurg Psychiatry 1988;51:745–752.Article PubMed PMC
8. Sung HY, Kim JS, Lee KS, Kim YI, Song IU, Chung SW, et al. The prevalence and patterns of pharyngoesophageal dysmotility in patients with early stage Parkinson’s disease. Mov Disord 2010;25:2361–2368.Article PubMed
9. Cersosimo MG, Benarroch EE. Neural control of the gastrointestinal tract: implications for Parkinson disease. Mov Disord 2008;23:1065–1075.Article PubMed
10. Vanek AW, Diamant NE. Responses of the human esophagus to paired swallows. Gastroenterology 1987;92:643–650.Article PubMed
11. Djaldetti R, Baron J, Ziv I, Melamed E. Gastric emptying in Parkinson’s disease: patients with and without response fluctuations. Neurology 1996;46:1051–1054.Article PubMed
12. Soykan I, Sivri B, Sarosiek I, Kiernan B, McCallum RW. Demography, clinical characteristics, psychological and abuse profiles, treatment, and long-term follow-up of patients with gastroparesis. Dig Dis Sci 1998;43:2398–2404.Article PubMed
13. Gurevich T, Korczyn AD, Giladi N. Gastric dysfunction. In: Pfeiffer RF, Bodis-Wollner I, editors. Parkinson’s disease and nonmotor dysfunction. New Jersey: Humana Press; 2005:105–113.Article
14. Kim JS, Sung HY, Lee KS, Kim YI, Kim HT. Anorectal dysfunctions in Parkinson’s disease. J Neurol Sci 2011;310:144–151.Article PubMed
15. Mathers SE, Kempster PA, Swash M, Lees AJ. Constipation and paradoxical puborectalis contraction in anismus and Parkinson’s disease: a dystonic phenomenon? J Neurol Neurosurg Psychiatry 1988;51:1503–1507.Article PubMed PMC
16. Mathers SE, Kempster PA, Law PJ, Frankel JP, Bartram CI, Lees AJ, et al. Anal sphincter dysfunction in Parkinson’s disease. Arch Neurol 1989;46:1061–1064.Article PubMed
17. Sung HY, Choi MG, Kim YI, Lee KS, Kim JS. Anorectal manometric dysfunctions in newly diagnosed, early-stage Parkinson’s disease. J Clin Neurol 2012;8:184–189.Article PubMed PMC
18. Sakakibara R, Odaka T, Uchiyama T, Asahina M, Yamaguchi K, Yamaguchi T, et al. Colonic transit time and rectoanal videomanometry in Parkinson’s disease. J Neurol Neurosurg Psychiatry 2003;74:268–272.Article PubMed PMC

Figure & Data

References

Citations

Citations to this article as recorded by

Neuroimmune Connectomes in the Gut and Their Implications in Parkinson’s Disease
Beatriz Thomasi, Luisa Valdetaro, Brian Gulbransen, Ana Lúcia Tavares-Gomes
Molecular Neurobiology.2024; 61(4): 2081. CrossRef
Effect of Lycium ruthenicum and Lycium barbarum intake on Parkinson based on microbiology and metabonomics: A randomized pilot trial
Lingyu Wu, Liwen Chu, Hongdou Cao, Qi Tian, Hua Gao, Jinghong Huo, Qinghan Gao
Food Bioscience.2024; 57: 103548. CrossRef
The missing piece of the puzzle – The key role of the dietitian in the management of Parkinson's disease
Richelle Flanagan, Carley Rusch, Fiona E. Lithander, Indu Subramanian
Parkinsonism & Related Disorders.2024; 121: 106021. CrossRef
Gastric-filling ultrasonography to evaluate gastric motility in patients with Parkinson's disease
Xianwei Zou, Xiaqing Chen, Yanxia Wen, Xiaofeng Jing, Man Luo, Fengyue Xin, Yao Tang, Mengfei Hu, Jian Liu, Fan Xu
Frontiers in Neurology.2024;[Epub] CrossRef
Persistent intolerable abdominal pain in patients with Parkinson’s disease
Hiroshi Kataoka, Kazuma Sugie
Clinical Neurology and Neurosurgery.2023; 224: 107558. CrossRef
Striatal Dopaminergic Loss and Dysphagia in Parkinson Disease
Ji Hwan Kim, Jonghu Jeon, Young Lee, Seung Min Kim, Miju Cheon, Jun Yup Kim
Clinical Nuclear Medicine.2023; 48(2): 143. CrossRef
The gut microbiota is an emerging target for improving brain health during ageing
Marcus Boehme, Katherine Elizabeth Guzzetta, Caroline Wasén, Laura Michelle Cox
Gut Microbiome.2023;[Epub] CrossRef
6-OHDA-Induced Changes in Colonic Segment Contractility in the Rat Model of Parkinson’s Disease
Maria Del Pilar Murillo, Ebba Johansson, Victoria Bryntesson, Patrik Aronsson, Gunnar Tobin, Michael Winder, Thomas Carlsson, Stephen Fink
Gastroenterology Research and Practice.2023; 2023: 1. CrossRef
Efficacy of acupuncture for the treatment of Parkinson’s disease-related constipation (PDC): A randomized controlled trial
Ying-Jia Li, Ian-I Leong, Jing-Qi Fan, Ming-Yue Yan, Xin Liu, Wei-Jing Lu, Yuan-Yuan Chen, Wei-Qiang Tan, Yu-Ting Wang, Li-Xing Zhuang
Frontiers in Neuroscience.2023;[Epub] CrossRef
Considerations for developing a targeted amino acid supplement for people with Parkinson’s disease that promotes health while accounting for pathophysiology and medication interference
Jacob E Earp, Cristina Colon-Semenza, Dara L LoBuono
Nutrition Reviews.2023; 81(8): 1063. CrossRef
Lactobacillus plantarum CCFM405 against Rotenone-Induced Parkinson’s Disease Mice via Regulating Gut Microbiota and Branched-Chain Amino Acids Biosynthesis
Chuanqi Chu, Leilei Yu, Yiwen Li, Hang Guo, Qixiao Zhai, Wei Chen, Fengwei Tian
Nutrients.2023; 15(7): 1737. CrossRef
The longitudinal progression of autonomic dysfunction in Parkinson's disease: A 7-year study
Charlotte B. Stewart, David Ledingham, Victoria K. Foster, Kirstie N. Anderson, Sahana Sathyanarayana, Debra Galley, Nicola Pavese, Jacopo Pasquini
Frontiers in Neurology.2023;[Epub] CrossRef
Association of dysphagia with altered brain glucose metabolism in Parkinson's disease
Ji Yeon Oh, Eui Jin An, Young Lee, Seung Min Kim, Miju Cheon, Jun Yup Kim
CNS Neuroscience & Therapeutics.2023; 29(9): 2498. CrossRef
Differential Findings on Anorectal Manometry in Patients with Parkinson's Disease and Defecatory Dysfunction
Wendy Zhou, George Triadafilopoulos, Brooke Gurland, Houssam Halawi, Laren Becker, Patricia Garcia, Linda Nguyen, Mitchell Miglis, Srikanth Muppidi, Dong‐In Sinn, Safwan Jaradeh, Leila Neshatian
Movement Disorders Clinical Practice.2023; 10(7): 1074. CrossRef
Abdominal pain in Parkinson’s disease
A.A. Pilipovich, O.V. Vorobyova, S.A. Makarov
Russian Journal of Pain.2023; 21(2): 12. CrossRef
Microbiome-Based Therapies in Parkinson’s Disease: Can Tuning the Microbiota Become a Viable Therapeutic Strategy?
Adejoke Y. Onaolapo, Folusho O. Ojo, Anthony T. Olofinnade, Joshua Falade, Ismail A. Lawal, Olakunle J. Onaolapo
CNS & Neurological Disorders - Drug Targets.2023; 22(9): 1355. CrossRef
Constipation in Parkinson's Disease
Eamonn M. M. Quigley
Seminars in Neurology.2023; 43(04): 562. CrossRef
Autonomic symptoms in early-stage Parkinson’s patients and their relationship with cognition and disease parameters
Esma KOBAK TUR, Eren GÖZKE
Anatolian Current Medical Journal.2023; 5(4): 498. CrossRef
Lower gastrointestinal dysfunction in patients with Parkinson’s disease
A.A. Pilipovich, O.V. Vorob’eva, S.A. Makarov, A.V. Kuchuk
Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova.2023; 123(12): 42. CrossRef
Related Effects of Methamphetamine on the Intestinal Barrier via Cytokines, and Potential Mechanisms by Which Methamphetamine May Occur on the Brain-Gut Axis
Yuansen Li, Deshenyue Kong, Ke Bi, Huayou Luo
Frontiers in Medicine.2022;[Epub] CrossRef
Alpha-synuclein and tau are abundantly expressed in the ENS of the human appendix and monkey cecum
Alexandra D. Zinnen, Jonathan Vichich, Jeanette M. Metzger, Julia C. Gambardella, Viktoriya Bondarenko, Heather A. Simmons, Marina E. Emborg, Stephan N. Witt
PLOS ONE.2022; 17(6): e0269190. CrossRef
Management of dysphagia and gastroparesis in Parkinson’s disease in real-world clinical practice – Balancing pharmacological and non-pharmacological approaches
Roongroj Bhidayasiri, Warongporn Phuenpathom, Ai Huey Tan, Valentina Leta, Saisamorn Phumphid, K. Ray Chaudhuri, Pramod Kumar Pal
Frontiers in Aging Neuroscience.2022;[Epub] CrossRef
Mechanisms of development of constipation in Parkinson’s disease and therapeutic approaches
E.A. Katunina, N.N. Shipilova, D.A. Katunin
Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova.2022; 122(8): 21. CrossRef
Intestinal Permeability, Dysbiosis, Inflammation and Enteric Glia Cells: The Intestinal Etiology of Parkinson’s Disease
Huijia Yang, Song Li, Weidong Le
Aging and disease.2022; 13(5): 1381. CrossRef
The interplay between the gut-brain axis and the microbiome: A perspective on psychiatric and neurodegenerative disorders
Yasir Bashir, Asad U. Khan
Frontiers in Neuroscience.2022;[Epub] CrossRef
Clinical features and relative factors of constipation in a cohort of Chinese patients with Parkinson's disease
Bai-Hua Sun, Tao Wang, Nian-Ying Li, Qiong Wu, Jin Qiao
World Journal of Gastrointestinal Pharmacology and Therapeutics.2021; 12(1): 21. CrossRef
Characterization of Gastrointestinal Symptom Type and Severity in Parkinson's Disease: A Case–Control Study in an Australian Cohort
Jade E. Kenna, Megan C. Bakeberg, Anastazja M. Gorecki, Alfred Chin Yen Tay, Samantha Winter, Frank L. Mastaglia, Ryan S. Anderton
Movement Disorders Clinical Practice.2021; 8(2): 245. CrossRef
Granisetron, a selective 5-HT3 antagonist, reduces L-3,4-dihydroxyphenylalanine-induced abnormal involuntary movements in the 6-hydroxydopamine-lesioned rat
Cynthia Kwan, Imane Frouni, Dominique Bédard, Adjia Hamadjida, Philippe Huot
Behavioural Pharmacology.2021; 32(1): 43. CrossRef
Deglutition Impairment during Dual Task in Parkinson Disease Is Associated with Cognitive Status
Luciana Grolli Ardenghi, Alana Verza Signorini, Gerson Schulz Maahs, Fabio Selaimen, Konrado Massing Deutsch, Silvia Dornelles, Carlos Roberto de Mello Rieder
International Archives of Otorhinolaryngology.2021; 25(01): e41. CrossRef
Spectrum of Non-Motor Symptoms in Parkinson's Disease
Maithrayie Kumaresan, Safeera Khan
Cureus.2021;[Epub] CrossRef
Onset of Skin, Gut, and Genitourinary Prodromal Parkinson's Disease: A Study of 1.5 Million Veterans
Gregory D. Scott, Miranda M. Lim, Matthew G. Drake, Randy Woltjer, Joseph F. Quinn
Movement Disorders.2021; 36(9): 2094. CrossRef
The Gastrointestinal Dysfunction Scale for Parkinson's Disease
Marta Camacho, Julia C. Greenland, Caroline H. Williams‐Gray
Movement Disorders.2021; 36(10): 2358. CrossRef
The role of microbiota-gut-brain axis in neuropsychiatric and neurological disorders
Katarzyna Socała, Urszula Doboszewska, Aleksandra Szopa, Anna Serefko, Marcin Włodarczyk, Anna Zielińska, Ewa Poleszak, Jakub Fichna, Piotr Wlaź
Pharmacological Research.2021; 172: 105840. CrossRef
Neuro-Immunity and Gut Dysbiosis Drive Parkinson’s Disease-Induced Pain
Katiane Roversi, Natalia Callai-Silva, Karine Roversi, May Griffith, Christos Boutopoulos, Rui Daniel Prediger, Sébastien Talbot
Frontiers in Immunology.2021;[Epub] CrossRef
Autonomic dysfunction in Parkinson’s disease: Implications for pathophysiology, diagnosis, and treatment
Zhichun Chen, Guanglu Li, Jun Liu
Neurobiology of Disease.2020; 134: 104700. CrossRef
Double‐Blind, Randomized, Placebo‐Controlled Trial of DA‐9701 in Parkinson's Disease: PASS‐GI Study
Ji‐Hyun Choi, Jee‐Young Lee, Jin Whan Cho, Seong‐Beom Koh, Young Soon Yang, Dalla Yoo, Cheol‐Min Shin, Hee Tae Kim
Movement Disorders.2020; 35(11): 1966. CrossRef
Parkinson disease and the gut: new insights into pathogenesis and clinical relevance
R. Alberto Travagli, Kirsteen N. Browning, Michael Camilleri
Nature Reviews Gastroenterology & Hepatology.2020; 17(11): 673. CrossRef
Expanding the brain researcher's toolkit
Viviana Gradinaru
Science.2020; 369(6504): 637. CrossRef
Excessive buccal saliva in patients with Parkinson’s disease of the French COPARK cohort
Olivier Rascol, Laurence Negre-Pages, Philippe Damier, Arnaud Delval, Pascal Derkinderen, Alain Destée, Margherita Fabbri, Wassilios G. Meissner, Amine Rachdi, François Tison, Santiago Perez-Lloret
Journal of Neural Transmission.2020; 127(12): 1607. CrossRef
Struktur und Efferenzen der Substantia nigra pars compacta beim idiopathischen Parkinson-Syndrom
Peter Urban, Bjorn Falkenburger, Wolfgang H. Jost, Gerhard Ransmayr, Peter Riederer, Christian Winkler
Fortschritte der Neurologie · Psychiatrie.2020; 88(09): 591. CrossRef
Parkinson’s disease: Are gut microbes involved?
Yogesh Bhattarai, Purna C. Kashyap
American Journal of Physiology-Gastrointestinal and Liver Physiology.2020; 319(5): G529. CrossRef
Does Bilateral Deep Brain Stimulation of the Subthalamic Nucleus Modify Ano-Rectal Motility in Parkinson’s Disease? Results of a Randomized Cross-Over Study
Guillaume Gourcerol, David Maltete, Nathalie Chastan, Marie Laure Welter, Anne Marie Leroi, Stéphane Derrey
Neuromodulation: Technology at the Neural Interface.2019; 22(4): 478. CrossRef
Probiotics for Parkinson’s Disease
Gazerani
International Journal of Molecular Sciences.2019; 20(17): 4121. CrossRef
Colon dysregulation in methamphetamine self-administering HIV-1 transgenic rats
Amanda L. Persons, Brinda D. Bradaric, Hemraj B. Dodiya, Michael Ohene-Nyako, Christopher B. Forsyth, Ali Keshavarzian, Maliha Shaikh, T. Celeste Napier, Shilpa J. Buch
PLOS ONE.2018; 13(1): e0190078. CrossRef
Induction of alpha-synuclein pathology in the enteric nervous system of the rat and non-human primate results in gastrointestinal dysmotility and transient CNS pathology
Fredric P. Manfredsson, Kelvin C. Luk, Matthew J. Benskey, Aysegul Gezer, Joanna Garcia, Nathan C. Kuhn, Ivette M. Sandoval, Joseph R. Patterson, Alana O'Mara, Reid Yonkers, Jeffrey H. Kordower
Neurobiology of Disease.2018; 112: 106. CrossRef
Dysbiosis of gut microbiota and microbial metabolites in Parkinson’s Disease
Meng-Fei Sun, Yan-Qin Shen
Ageing Research Reviews.2018; 45: 53. CrossRef
Parkinson’s Disease and Current Treatments for Its Gastrointestinal Neurogastromotility Effects
Chethan Ramprasad, Jane Yellowlees Douglas, Baharak Moshiree
Current Treatment Options in Gastroenterology.2018; 16(4): 489. CrossRef
Transdermal rotigotine patch in Parkinson’s disease with a history of intestinal operation
Takashi Ogawa, Genko Oyama, Nobutaka Hattori
BMJ Case Reports.2018; : bcr-2017-223722. CrossRef
α-Synuclein in the colon and premotor markers of Parkinson disease in neurologically normal subjects
Joong-Seok Kim, In-Seok Park, Hyung-Eun Park, Su-Young Kim, Jung A Yun, Chan Kwon Jung, Hye-Young Sung, Jin-Kwon Lee, Won-Kyung Kang
Neurological Sciences.2017; 38(1): 171. CrossRef
The Threshold Theory for Parkinson's Disease
Simone Engelender, Ole Isacson
Trends in Neurosciences.2017; 40(1): 4. CrossRef
Constipation in parkinson's disease: Subjective symptoms, objective markers, and new perspectives
Karoline Knudsen, Klaus Krogh, Karen Østergaard, Per Borghammer
Movement Disorders.2017; 32(1): 94. CrossRef
Is Levodopa Pharmacokinetics in Patients with Parkinson’s Disease Depending on Gastric Emptying?
Maria Nord, Anita Kullman, Ulf Hannestad, Nil Dizdar
Advances in Parkinson's Disease.2017; 06(01): 1. CrossRef
Validation of the Korean Version of the Scale for Outcomes in Parkinson’s Disease-Autonomic
Ji-Young Kim, In-Uk Song, Seong-Beom Koh, Tae-Beom Ahn, Sang Jin Kim, Sang-Myung Cheon, Jin Whan Cho, Yun Joong Kim, Hyeo-Il Ma, Mee-Young Park, Jong Sam Baik, Phil Hyu Lee, Sun Ju Chung, Jong-Min Kim, Han-Joon Kim, Young-Hee Sung, Do Young Kwon, Jae-Hyeo
Journal of Movement Disorders.2017; 10(1): 29. CrossRef
Gastroesophageal reflux disease with proton pump inhibitor use is associated with an increased risk of osteoporosis: a nationwide population-based analysis
C.-H. Chen, C.-L. Lin, C.-H. Kao
Osteoporosis International.2016; 27(6): 2117. CrossRef
Parkinson Disease-Mediated Gastrointestinal Disorders and Rational for Combinatorial Therapies
Syed Ali, Ning Yin, Arkam Rehman, Verline Justilien
Medical Sciences.2016; 4(1): 1. CrossRef
Intestinal dysfunction in Parkinson's disease: Lessons learned from translational studies and experimental models
C. Pellegrini, R. Colucci, L. Antonioli, E. Barocelli, V. Ballabeni, N. Bernardini, C. Blandizzi, W. J. de Jonge, M. Fornai
Neurogastroenterology & Motility.2016; 28(12): 1781. CrossRef
Gut dysfunction in Parkinson's disease
Adreesh Mukherjee, Atanu Biswas, Shyamal Kumar Das
World Journal of Gastroenterology.2016; 22(25): 5742. CrossRef
Inflammation is genetically implicated in Parkinson’s disease
N. Dzamko, C.L Geczy, G.M Halliday
Neuroscience.2015; 302: 89. CrossRef
Alteration of enteric monoamines with monoamine receptors and colonic dysmotility in 6-OHDA-induced Parkinson’s disease rats
Xiaoli Zhang, Yun Li, Chenzhe Liu, Ruifang Fan, Ping Wang, Lifei Zheng, Feng Hong, Xiaoyan Feng, Yue Zhang, Lisheng Li, Jinxia Zhu
Translational Research.2015;[Epub] CrossRef
The treatment of gastroparesis, constipation and small intestinal bacterial overgrowth syndrome in patients with Parkinson’s disease
Jose L Barboza, Michael S Okun, Baharak Moshiree
Expert Opinion on Pharmacotherapy.2015; 16(16): 2449. CrossRef
Gastrointestinal Dysfunctions in Parkinson’s Disease
Joong-Seok Kim, Hey Young Sung
Journal of the Korean Neurological Association.2015; 33(4): 247. CrossRef



info You must log in with your e-submission system account. (https://submit.e-jmd.org)